Last edition
News about "TYK2 inhibitor"
Bristol Myers Squibb Secures EC Approval for Sotyktu in Psoriatic Arthritis
Bristol Myers Squibb receives European Commission (EC) approval for Sotyktu to treat active psoriatic arthritis in adults, marking the EU’s first approved TYK2 inhibitor for this indication.
TYK2 Inhibitor | 12/05/2026 | By News Bureau
Alumis and Kaken Pharmaceutical to Develop ESK-001 in Dermatology in Japan
Under the terms of the agreement, Alumis will receive USD 40 million in upfront and near-term co-development payments from 2025 to 2026, with the potential to earn up to approximately USD 140 million in additional payments based on the achievement of milestones, and field option payments.
TYK2 Inhibitor | 28/03/2025 | By Aishwarya | 426
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy